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Over the last few decades research on the cannabin-
oids has gone through several distinct phases:
A. Research on plant cannabinoids (mostly on tetrahy-
drocannabinol (THC) and cannabidiol (CBD))
B. Research on endogenous cannabinoids (mostly on
anandamide and 2-arachidonoyl glycerol (2-AG))
C. Research on endogenous anandamide-like endogen-
ous fatty acid amides with amino acids and ethanol
amines.
Plant cannabinoids While many dozens of plant
cannabinoids are known today, most research is still on
THC and CBD (Fig. 1).
CBD was isolated in the late 1930s, but its structure
was elucidated only in 1963 (Mechoulam & Shvo, 1963).
In 1964, when its structure was elucidated, pure THC
was isolated (Gaoni & Mechoulam, 1964) and later syn-
thesized. The psychoactivity of cannabis preparations
(marijuana, hashish etc.) is mostly due to THC, but
the other constituents may affect the activity of THC.
Some of its metabolites are also psychoactive.
Thousands of publications have been published on the
plant cannabinoids and some of them are already in use
as therapeutic drugs. THC has been approved as a drug
(named Marinol) for enhancement of appetite, and is
also used to prevent vomiting due to cancer chemother-
apy (Abrahamov & Mechoulam, 1995).
Of particular interest is CBD, which does not cause
the typical cannabis psychoactivity, but is a potent anti-
epileptic drug (Cunha et al., 1980) and is used in many
countries in pediatric epilepsy. It is being evaluated in
other therapeutic areas (graft versus host disease, Ye-
shurun et al., 2015, schizophrenia, Leweke et al., 2012,
and auto-immune diseases, for example Weiss et al.,
2006).
The endogenous cannabinoids Anandamide
(Devane et al., 1992) and 2-arachidonoyl glycerol
(2-AG) (Mechoulam et al., 1995) were discovered in the
1990s. Both compounds bind to the cannabinoid re-
ceptors CB1 and CB2. They are involved in a very large
number of human diseases, mostly as neuroprotective
entities (Pacher & Kunos, 2013).
Endogenous fatty acid amides with amino acids
and ethanol amines A large number of compounds
of these types have been discovered in the brain and
other tissues, and some of them have been shown to
be of major importance in a large spectrum of biolo-
gical functions and diseases. Thus, oleoyl serine is an
anti-osteoporotic molecule (Smoum et al., 2010) and
arachidonoyl serine is a vasodilator and lowers brain
damage (Cohen-Yeshurun et al., 2011).
Numerous pharmaceutical companies are now in-
volved in research in all the above areas.
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Figure 1: Cannabinoid compounds.
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